According to the Legislative Budget Board (LBB), HB 4813 is not expected to have a significant fiscal impact on the state. The analysis indicates that any administrative costs incurred as a result of the bill’s implementation—primarily by the Department of State Health Services (DSHS) and the Health and Human Services Commission—can be absorbed within the agencies’ existing budgets and resources.

The fiscal neutrality is due in part to the procedural nature of the bill. HB 4813 does not create new programs or mandates requiring additional staffing or infrastructure. Instead, it modifies the workflow for updating the state's controlled substance schedules by allowing more immediate conformity with federal decisions, specifically those of the FDA. The bill thus may even reduce administrative overhead over time by minimizing the need for public hearings and repeated review cycles when federal scheduling changes occur.

Furthermore, the fiscal note also states that no significant fiscal implication is anticipated for local governments. The legislation does not impose new responsibilities or costs on counties, municipalities, or other local entities, since the authority and procedural changes it enacts are confined to state-level regulatory functions.

In summary, HB 4813 is expected to be cost-neutral while enhancing regulatory efficiency, making it a fiscally responsible measure with minimal budgetary impact.

HB 4813, as revised in the committee substitute, addresses a critical administrative delay in Texas’s scheduling of controlled substances by ensuring more immediate alignment with federal rescheduling decisions when the FDA approves a substance for medical use. The bill responds to growing concerns that the current annual review process often lags behind federal action, thereby delaying access to potentially life-saving treatments for patients suffering from mental health conditions such as treatment-resistant depression, PTSD, and major depressive disorder.

The bill's fiscal and criminal justice implications are minimal to nonexistent. The LBB determined there would be no significant fiscal impact to state or local governments, and the committee noted that the bill does not create or alter any criminal offenses. The targeted scope of the bill—focused specifically on FDA-approved substances that have been rescheduled or de-scheduled—helps ensure that changes only occur in medically validated cases, preserving the authority of the commissioner to object in specific instances if necessary.

Importantly, the substitute version of the bill expands its applicability beyond Schedule I substances to include any FDA-approved drug that undergoes a federal rescheduling action, further improving regulatory responsiveness and access to treatment. This change supports individual liberty and personal responsibility by allowing Texans and their healthcare providers to make timely decisions based on current medical evidence without waiting for redundant bureaucratic steps. It also upholds the principles of limited government and efficient public service.

Given its clear public health benefits, regulatory efficiency, negligible fiscal cost, and alignment with core liberty principles, HB 4813 deserves a favorable recommendation and should be passed. Texas Policy Research recommends that lawmakers vote YES on HB 4813.

• Individual Liberty: The bill directly advances individual liberty by removing procedural barriers that prevent patients from accessing medications approved by the FDA for legitimate medical use. This is particularly relevant for individuals with conditions such as PTSD, treatment-resistant depression, and other severe health issues. By ensuring Texas law promptly reflects changes to federal drug schedules, the bill affirms a person’s right to make timely healthcare decisions in consultation with their provider—free from outdated state restrictions.
• Personal Responsibility: HB 4813 empowers individuals and healthcare providers to act responsibly based on up-to-date science and treatment options approved by federal authorities. It recognizes that patients and physicians are capable of making informed decisions when a substance has been determined to be safe and effective for medical use. Removing the state’s redundant delay acknowledges that Texans can and should take responsibility for their own healthcare choices.
• Free Enterprise: By streamlining the alignment of state-controlled substance schedules with federal actions, the bill eliminates bureaucratic bottlenecks that can delay entry of innovative therapies and pharmaceutical products into the Texas market. This facilitates business operations, investment, and innovation in the state’s biotech and medical sectors, reinforcing a freer marketplace for healthcare-related enterprises.
• Private Property Rights: While not directly implicating traditional property rights (e.g., land or assets), HB 4813 upholds a broader interpretation of bodily autonomy—arguably the most personal form of property. By ensuring access to FDA-approved treatments without arbitrary delays, the bill respects an individual’s dominion over their own body and health decisions, albeit indirectly.
• Limited Government: The bill exemplifies limited government by reducing redundant layers of oversight. Instead of requiring the Texas Department of State Health Services to undergo a separate, lengthy rulemaking process after federal rescheduling, the bill mandates prompt adoption of those federal decisions. It maintains a safeguard by allowing the commissioner to object when appropriate, but generally minimizes unnecessary state intervention, streamlining governance in accordance with liberty-minded values.

• SB 2997 (Similar To)